Biomedical Engineering Reference
In-Depth Information
2009; 27: 672-680. Published on 20081229. doi:10.1200/
JCO.2008.19.8135.
45. Saltz LB, Lenz HJ, Kindler HL,
J Clin Oncol
Randomized phase II trial of
cetuximab, bevacizumab, and irinotecan compared with cetuximab
and bevacizumab alone in irinotecan-refractory colorectal cancer:
the BOND-2 study.
et al.
2007; 25: 4557-4561. Published on
20070917. doi:10.1200/JCO.2007.12.0949.
46. Rothenberg ML, LaFleur B, Levy DE,
J Clin Oncol
Randomized phase II trial
of the clinical and biological effects of two dose levels of gefitinib in
patients with recurrent colorectal adenocarcinoma.
et al.
J Clin Oncol
2005;
23: 9265-9274. doi:10.1200/JCO.2005.03.0536.
47. Townsley CA, Major P, Siu LL,
Phase II study of erlotinib (OSI-
774) in patients with metastatic colorectal cancer.
et al.
Br J Cancer
2006;
94: 1136-1143. doi:10.1038/sj.bjc.6603055.
48. Zampino MG, Magni E, Massacesi C,
First clinical experience of
orally active epidermal growth factor receptor inhibitor combined with
simplified FOLFOX6 as first-line treatment for metastatic colorectal
cancer.
et al.
2007; 110: 752-758. doi:10.1002/cncr.22851.
49. Kuo T, Cho CD, Halsey J,
Cancer
Phase II study of gefitinib, fluorouracil,
leucovorin, and oxaliplatin therapy in previously treated patients
with metastatic colorectal cancer.
et al.
J Clin Oncol
2005; 23: 5613-5619.
doi:10.1200/JCO.2005.08.359.
50. Meyerhardt JA, Zhu AX, Enzinger PC,
Phase II study of
capecitabine, oxaliplatin, and erlotinib in previously treated patients
with metastastic colorectal cancer.
et al.
J Clin Oncol
2006; 24: 1892-1897.
doi:10.1200/JCO.2005.05.3728.
51. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of
targeted inhibitors.
Nat Rev Cancer
2005; 5: 341-354. doi:10.1038/
nrc1609.
52. Albanell J, Rojo F, Averbuch S,
Pharmacodynamic studies of the
epidermal growth factor receptor inhibitor ZD1839 in skin from cancer
patients: histopathologic and molecular consequences of receptor
inhibition.
et al.
2002; 20: 110-124.
53. Baselga J, Rischin D, Ranson M,
J Clin Oncol
Phase I safety, pharmacokinetic,
and pharmacodynamic trial of ZD1839, a selective oral epidermal
growth factor receptor tyrosine kinase inhibitor, in patients with five
selected solid tumor types.
et al.
J Clin Oncol
2002; 20: 4292-4302.
54. Vanhoefer U, Tewes M, Rojo F,
Phase I study of the humanized
antiepidermal growth factor receptor monoclonal antibody EMD72000
in patients with advanced solid tumors that express the epidermal
et al.
